Hemostemix Grants Stock Options

Rhea-AI Summary

Hemostemix (OTCQB:HMTXF) granted, in accordance with its stock option plan and subject to regulatory approval, a total of 6,280,000 stock options on July 22, 2026 to directors, officers, employees and consultants. Of these, 4,535,000 options vest immediately, while 1,745,000 options vest 50% on July 22, 2026 and 50% on July 22, 2027. Following this grant, Hemostemix reports 20,496,694 options issued and outstanding, including 3,140,000 options granted to directors and officers.

According to Hemostemix, the grants to insiders rely on valuation and minority-approval exemptions under MI 61-101, as the fair market value is below 25% of market capitalization. The company highlights its autologous stem cell therapy platform, seven completed clinical studies involving 318 subjects, eleven peer-reviewed publications, and Phase II data for ACP-01 in chronic limb threatening ischemia, including reported 0% mortality and wound healing in 83% of patients followed up to 4.5 years.

Positive

• 6,280,000 new options granted to directors, officers, employees, consultants on July 22, 2026
• 20,496,694 options now issued and outstanding, improving disclosure of total option overhang
• 3,140,000 options allocated to directors and officers, aligning insider incentives with shareholders
• 7 clinical studies completed with 318 subjects and 11 peer-reviewed publications
• Phase II CLTI mid-point result: 0% mortality and 83% wound healing up to 4.5 years

Negative

• Grant of 6,280,000 new options adds to potential shareholder dilution, with 20,496,694 options outstanding post-grant

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Calgary, Alberta--(Newsfile Corp. - July 22, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that in accordance with its stock option plan, it has granted on July 22, 2026, subject to regulatory approval, a total of 6,280,000 options to purchase common shares of Hemostemix (the "Options") to directors, officers, employees and consultants.

Of the 6,280,000 Options granted, 4,535,000 Options vest immediately upon grant, and 1,745,000 Options vest as to 50% on July 22, 2026, and 50% on July 22, 2027. After this Option issuance, Hemostemix has 20,496,694 Options issued and outstanding. Of the Options granted, 3,140,000 Options were issued to directors and officers of Hemostemix. The Company relied on section 5.5(b) of Multilateral Instrument 61-101- Protection of Minority Security Holders in Special Transactions ("MI 61-101") as the exemption from the formal valuation requirements of MI 61-101 and TSX Venture Exchange Policy 5.9 in respect of the Options grant to the directors and officers of Hemostemix, as no securities of the Company are listed on a specified market as defined in MI 61-101. Hemostemix relied on section 5.7(a) of MI 61-101 as the exemption from the minority approval requirements of MI 61-101 and TSX Venture Exchange Policy 5.9 in respect of the Options grant to the directors and officers of the Company, as neither the fair market value of the subject matter of, nor the fair market value of the consideration for, the Options granted to the directors and officers of the Company exceeded 25% of Hemostemix' market capitalization. The Compensation Committee and Board of Directors of the Company have approved the Options grant and no materially contrary view or abstention was expressed or made by any director in relation to the Options grant. The material change report to be filed in relation to the Options grant will not be not filed at least 21 days prior to the completion of the Options grant as contemplated by MI 61-101. The Company believes that this shorter period is reasonable and necessary in the circumstances as the completion of the Options grant occurred shortly before the issuance of this news release and the filing of such material change report.

About Hemostemix

Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapy, VesCell™ an investigational autologous stem cell therapy developed to support circulation in areas affected by diseases of ischemia. VesCell™ is derived from a patient's own blood and evaluated through structured clinical research. Hemostemix has completed seven clinical studies of 318 subjects and published its results in eleven peer reviewed publications. ACP-01 is safe, and appears clinically relevant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five year mortality rate of 50% in the CLTI diabetes-based patient population, UBC and U of T reported to the 41st meeting of vascular surgeons: 0% mortality, cessation of pain, wound healing in 83% of patients followed for up to 4.5 years, as a midpoint result. For more information, please visit www.hemostemix.com.

For further information, please contact:

Thomas Smeenk, President and CEO, EM: tsmeenk@hemostemix.com , PH: 905-580-4170

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to, but is not limited to, the grant of stock options. Forward-looking information is based on assumptions and involves known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied by such forward-looking information, including the risk that the restatement process and adjustments may change, or that the non-brokered private placement may not close. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of any litigation that Hemostemix is pursuing or defending (the "Litigation"), if any; the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and, Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR+ website at www.sedarplus.ca. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/306143

FAQ

What stock options did Hemostemix (OTCQB:HMTXF) grant on July 22, 2026?

Hemostemix granted 6,280,000 stock options on July 22, 2026, subject to regulatory approval. According to Hemostemix, 4,535,000 options vest immediately and 1,745,000 vest 50% on July 22, 2026 and 50% on July 22, 2027.

How many Hemostemix (HMTXF) stock options went to directors and officers in July 2026?

Hemostemix granted 3,140,000 options to its directors and officers as part of the July 22, 2026 issuance. According to Hemostemix, these insider grants relied on exemptions under MI 61-101 for valuation and minority-approval requirements.

How many stock options does Hemostemix (HMTXF) have outstanding after the July 2026 grant?

After the July 22, 2026 option grant, Hemostemix reports 20,496,694 stock options issued and outstanding. According to Hemostemix, this total includes the newly granted 6,280,000 options to directors, officers, employees and consultants under its stock option plan.

What does the July 2026 Hemostemix stock option grant mean for HMTXF shareholders?

The grant adds 6,280,000 options, increasing potential future dilution but aligning compensation with equity performance. According to Hemostemix, 3,140,000 options went to directors and officers, and total outstanding options rose to 20,496,694 after the transaction.

What clinical results has Hemostemix reported for ACP-01 in chronic limb threatening ischemia?

Hemostemix states ACP-01 is safe and appears clinically relevant in chronic limb threatening ischemia. According to Hemostemix, UBC and U of T reported 0% mortality and wound healing in 83% of patients followed up to 4.5 years in its Phase II trial.

What is Hemostemix VesCell autologous stem cell therapy platform?

VesCell is Hemostemix’s autologous blood-based stem cell therapy designed to support circulation in ischemic diseases. According to Hemostemix, it is derived from a patient’s own blood, evaluated through structured clinical research, and supported by seven clinical studies and eleven peer-reviewed publications.

How does Hemostemix use MI 61-101 exemptions for its July 2026 option grant?

Hemostemix relied on MI 61-101 sections 5.5(b) and 5.7(a) for the grants to directors and officers. According to Hemostemix, no formal valuation or minority approval was required because the grant’s fair market value was below 25% of market capitalization.